New obesity drug KN069 enters first human tests
NCT ID NCT06547775
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called KN069 in 36 Chinese men who are overweight or obese. The main goal is to check if the drug is safe and how the body processes it. Researchers will also look at weight and waist changes over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN069
- What this could lead to
- If successful, this could lead to a new weight-loss drug for people with obesity or overweight.
- What could go wrong
- This is a very early Phase 1 trial with only 36 participants, so safety and effectiveness are not yet proven. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial